AZD4076 + Placebo
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-alcoholic Steatohepatitis (NASH)
Conditions
Non-alcoholic Steatohepatitis (NASH)
Trial Timeline
Nov 24, 2015 → Oct 27, 2025
NCT ID
NCT02612662About AZD4076 + Placebo
AZD4076 + Placebo is a phase 1 stage product being developed by AstraZeneca for Non-alcoholic Steatohepatitis (NASH). The current trial status is completed. This product is registered under clinical trial identifier NCT02612662. Target conditions include Non-alcoholic Steatohepatitis (NASH).
What happened to similar drugs?
0 of 4 similar drugs in Non-alcoholic Steatohepatitis (NASH) were approved
Approved (0) Terminated (0) Active (4)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02826525 | Phase 1 | Completed |
| NCT02612662 | Phase 1 | Completed |
Competing Products
20 competing products in Non-alcoholic Steatohepatitis (NASH)